[1] Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med, 2000, 41(10): 1704-1713.
[2] Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch, 2001, 439(6): 787-797.
[3] Rabinowitz I, Telepak R, Lee FC. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Clin Nucl Med, 2002, 27(7): 499-502.
[4] Reubi JC. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology, 2004, 80 Suppl 1:51-56.
[5] Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab, 2005, 19(2): 265-276.  doi: 10.1016/j.beem.2004.11.016
[6] Gotthardt M, Behe MP, Alfke H, et al. Imaging lung tumors with peptide-based radioligands. Clin Lung Cancer, 2003, 5(2): 119-124.
[7] Hofland LJ, Lamberts SW, van Hagen PM, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med, 2003, 44(8): 1315-1321.
[8] Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci, 1982, 31(11): 1133-1140.
[9] 王丽华, 汪勇先, 尹端沚.生长抑素及其类似物的标记技术的发展.核技术, 2003, 26(7): 537-544.  doi: 10.3321/j.issn:0253-3219.2003.07.012
[10] 徐文贵, 马庆杰, 张建中, 等.肿瘤特异性受体显像剂Octreotide(奥曲肽)的99Tcm标记与纯化方法研究.中国老年学杂志, 2004, 24(12): 1133-1134.  doi: 10.3969/j.issn.1005-9202.2004.12.017
[11] 武凤玉, 左书耀.放射性核素标记奥曲肽肿瘤受体显像研究进展.国外医学肿瘤学分册, 2005, 32(10): 760-763.
[12] 武鸿文, 管昌田, 梁正路, 等.肿瘤生长抑素受体显像剂99Tcm-octreotide的制备及鉴定.中华核医学杂志, 2000, 20(3): 112-116.  doi: 10.3760/cma.j.issn.2095-2848.2000.03.005
[13] 武鸿文, 管昌田, 梁正路. 99Tcm直接法标记Octreotide.同位素, 2000, 13(3): 152-156.  doi: 10.3969/j.issn.1000-7512.2000.03.005
[14] 王叙馥, 左书耀, 邵文博, 等.肿瘤受体显像剂99Tcm-octreotide的放化纯度分析.同位素, 2003, 16(01): 26-29.  doi: 10.3969/j.issn.1000-7512.2003.01.006
[15] 章斌. 188Re直接标记octreotide的方法学.国外医学放射医学核医学分册, 2002, 26(5): 220-222.
[16] Thakur ML, Kolan HR, Rifat S, et al. Vapreotide label with 99mTc for imaging tumor. Int J Oncol, 1996, 6: 445-451.
[17] 马庆杰, 徐文贵, 张建中, 等. SnCl2还原法生长抑素受体显像剂99Tcm-octreotide(奥曲肽)的生物活性研究.中国老年学杂志, 2004, 24(11): 1048-1049.  doi: 10.3969/j.issn.1005-9202.2004.11.029
[18] 景红丽, 李方, 杜延荣, 等. 99mTc-HYNIC-TOC生长抑素受体显像诊断胰腺神经内分泌肿瘤的临床应用.胃肠病学, 2008, 13(4): 195-199.  doi: 10.3969/j.issn.1008-7125.2008.04.002
[19] 王胜军, 汪静, 邓敬兰, 等. 99Tcm-HYNIC-Octreotide的标记及其在脑膜瘤诊断中的初步应用.中国临床医学影像杂志, 2008, 19(8): 551-554.  doi: 10.3969/j.issn.1008-1062.2008.08.006
[20] 邓念英, 张金山, 冼有卿. 99mTc-奥曲肽和99mTc-MIBI显像在乳腺癌临床的应用价值.中国普外基础与临床杂志, 2004, 11(1): 17-19.  doi: 10.3969/j.issn.1007-9424.2004.01.007
[21] 段炼, 李险峰, 陆克义, 等. 99Tcm-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用.中华眼科杂志, 2006, 42(12): 1068-1072.  doi: 10.3760/j:issn:0412-4081.2006.12.004
[22] 武鸿文, 管昌田, 李云春. 99mTc-octreotide的动物体内分布、药物动力学和临床初步应用研究.华西医科大学学报, 2000, 31(4): 481-484.
[23] 王佳琼, 王自正, 姚薇萱, 等. 99mTc-MIBI与99mTc-Octreotide生长抑素受体显像诊断乳腺癌的对比研究.中国医学影像学杂志, 2006, 14(2): 91-93.  doi: 10.3969/j.issn.1005-5185.2006.02.004
[24] Cwikla J B, Mikolajczak R, Pawlak D, et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med, 2008, 49(7): 1060-1065.  doi: 10.2967/jnumed.107.046961
[25] Gomez M, Ferrando R, Vilar J, et al. 99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract. Acta Gastroenterol Latinoam, 2010, 40(4): 332-338.
[26] Jing H, Li F, Chen L, et al. Detection of recurrent pancreatic primitive neuroectodermal tumor by tc-99m hydrazinonicotinyl-tyr3-octreotide scan. Clin Nucl Med, 2011, 36(1): 54-55.
[27] Sepulveda-Mendez J, de Murphy CA, Pedraza-Lopez M, et al. Specificity and sensitivity of 99mTc-EDDA/HYNIC-Tyr(3)-oc-treotide (99mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun, 2012, 33(1): 69-79.
[28] 王峰, 王自正, 姚薇萱, 等. 99Tcm-生长抑素受体显像对肺癌的诊断价值.中华结核和呼吸杂志, 2005, 28(4): 218-220.  doi: 10.3760/j:issn:1001-0939.2005.04.002
[29] 王叙馥.放射性核素标记奥曲肽诊断小细胞肺癌的研究进展.国外医学放射医学核医学分册, 2003, 27(1): 11-13.
[30] Nocun A, Chrapko B, Golebiewska R, et al. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy. Nucl Med Commun, 2011, 32(6): 522-529.
[31] 何小江, 黄劲雄, 陈贵兵, 等. 99mTc-奥曲肽显像和X线钼靶诊断乳腺癌.中国医学影像技术, 2009, 25(10): 1892-1895.  doi: 10.3321/j.issn:1003-3289.2009.10.044
[32] Chen L, Li F, Zhuang H, et al. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med, 2009, 50(3): 397-400.
[33] Czepczynski R, Kosowicz J, Mikolajczak R, et al. New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma. Pol Arch Med Wewn, 2006, 116(3): 853-860.
[34] Kurtaran A, Scheuba C, Kaserer K, et al. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. J Nucl Med, 1998, 39(11): 1907-1909.
[35] 赵德善, 乔振华, 张伟华, 等. 99Tcm-奥曲肽显像在淋巴瘤诊断中的应用.中华核医学杂志, 2007, 27(4): 224-226.  doi: 10.3760/cma.j.issn.2095-2848.2007.04.009
[36] 吴培仁, 何小江, 许林, 等. 99Tcm奥曲肽核素显像诊断结直肠癌的研究.中华肿瘤防治杂志, 2010, 17(5): 381-383.
[37] Gambini JP, Lopez LJ, Quagliata A, et al. 99mTc-HYNIC octreotide in neuroblastoma. Ann Nucl Med, 2008, 22(9): 817-819.  doi: 10.1007/s12149-008-0201-9
[38] Kukwa W, Andrysiak R, Kukwa A, et al. 99mTc-octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasop-haryngeal angiofibromas. Head Neck, 2011, 33(12): 1739-1746.  doi: 10.1002/hed.21668
[39] 李眉, 戴皓洁, 王雪, 等. 99mTc-奥曲肽SPECT/CT评价甲状腺相关性眼病活动期.中国医学影像技术, 2011, 27(3): 505-509.
[40] Sun H, Jiang XF, Wang S, et al. 99mTc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy(GO). Endocrine, 2007, 31(3): 305-310.
[41] 蔡胜, 袁岩, 姜玉新, 等.瘤原性佝偻病致病肿瘤的影像定位诊断.中国医学影像技术, 2006, 22(12): 1873-1876.  doi: 10.3321/j.issn:1003-3289.2006.12.028
[42] 张化冰, 潘慧, 李方, 等.奥曲肽显像诊断肿瘤性骨软化一例.中华医学杂志, 2005, 85(33): 2375-2376.  doi: 10.3760/j:issn:0376-2491.2005.33.020